Jaguar Health Announces New Patent Issued In Hong Kong For Napo Pharmaceuticals' Crofelemer In Treating Short Bowel Syndrome And Related Conditions
Portfolio Pulse from Benzinga Newsdesk
Jaguar Health has announced a new patent issued in Hong Kong for Napo Pharmaceuticals' Crofelemer, aimed at treating short bowel syndrome and related conditions. The company is also supporting proof-of-concept studies for rare disease indications, with results expected by the end of 2024 and 2025.
August 19, 2024 | 2:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jaguar Health has received a new patent in Hong Kong for Crofelemer, which could enhance its market position in treating short bowel syndrome. The company is also conducting studies for rare diseases, with results anticipated by 2024-2025.
The issuance of a new patent in Hong Kong for Crofelemer could potentially open new markets and revenue streams for Jaguar Health, positively impacting its stock. Additionally, ongoing studies for rare diseases could lead to future product developments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100